Obesity Launches Reinforce GLP-1 Growth, but Valuations Are Rich

With the demand for obesity drug therapies surging, a new generation of medicines with efficacy and minor tolerability issues has replaced older drugs. Over the next 10 years, we predict Novo Nordisk and Eli Lilly will lead the obesity market over the next 10 years with new therapies launching expected to launch beginning in 2026.

In this report, Morningstar researchers examine two competing companies with obesity and their impact on the global obesity drug market.